Statins improve cardiac endothelial function to prevent heart failure with preserved ejection fraction through upregulating circRNA-RBCK1

Heart failure with preserved ejection fraction (HFpEF) is associated with endothelial dysfunction. We have previously reported that statins prevent endothelial dysfunction through inhibition of microRNA-133a (miR-133a). This study is to investigate the effects and the underlying mechanisms of statins on HFpEF. Here, we show that statins upregulate the expression of a circular RNA (circRNA-RBCK1) which is co-transcripted with the ring-B-box-coiled-coil protein interacting with protein kinase C-1 (RBCK1) gene. Simultaneously, statins increase activator protein 2 alpha (AP-2α) transcriptional activity and the interaction between circRNA-RBCK1 and miR-133a. Furthermore, AP-2α directly interacts with RBCK1 gene promoter in endothelial cells. In vivo, lovastatin improves diastolic function in male mice under HFpEF, which is abolished by loss function of endothelial AP-2α or circRNA-RBCK1. This study suggests that statins upregulate the AP-2α/circRNA-RBCK1 signaling to suppress miR-133a in cardiac endothelial cells and prevent diastolic dysfunction in HFpEF.

� D A description of all covariates tested D � A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons D � A full description of the statistical parameters including central tendency (e.g.means) or other basic estimates (e.g.regression coefficient) JA.J AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g.confidence intervals) For null hypothesis testing, the test statistic (e.g.F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Give P values as exact values whenever suitable.
For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes Estimates of effect sizes (e.g.Cohen's d, Pearson's r), indicating how they were calculated

Policy information about availability of data
All manuscripts must include a data availability statement.This statement should provide the following information, where applicable: -Accession codes, unique identifiers, or web links for publicly available datasets -A description of any restrictions on data availability -For clinical datasets or third party data, please ensure that the statement adheres to our QQ!ig Data supporting the findings of this study are available within the article and its Supplementary Information files.Source data are provided with this paper. ) Research involving human participants, their data, or biological material Policy information about studies with human participants or human data.See also policy information about sex, gender (identity/presentation). and sexual orientation and race.ethnicity and racism.

No hum1n ltudy
Reporting on race, ethnicity, or

Ethics oversight
No humon 11ucly Note thatfull information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting
Please select the one below that is the best fit for your research.If you are not sure, read the appropriate sections before making your selection.

Life sciences study design
All studies must disclose on these points even when the disclosure is negative.

Behavioural & social sciences study design
All studies must disclose on these points even when the disclosure is negative.

Study description
Research sample Policy information about availability of computer code Data collection Data analysis IBM SPSS statistics 20.0 (IBM Corp., Armonk, NY, USA) GraphPad Prism version 8 (GraphPad Software, San Diego, CA, USA, www.graphpad.com)For manuscripts utilizing custom algorithms or software that are ce ntral to the research but not yet described in published literature, software must be made available to editors and reviewers.We strongly encourage code deposition in a community repository (e.g.GitHub).See the Nature Portfolio gujdelines for submjttjng code & software for further information.
All studies must disclose on these points even when the disclosure is negative.from authors about some types of materials, experimental systems and methods used in many studies.Here, indicate whether each material, system or method listed is relevant to your study.If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.(RaWt mAb, REACTIVIH MR Mk.SHNSITIVITYEndogenous.MW (kl},) 37, SOURCE Rabbit.Application WB IP IHC ChlP IP 4. vo:o Wlllebnmd Fa-/VWP Antibody 1)'8/86): tlblefor: WB,IP,IP andlHCO')